Make sure to sign up for an account today for exclusive coupons and free shipping on orders over $75!
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 25812-30-0 | Product Number: G0368
Gemfibrozil
×
![]()
×
Purity: >98.0%(GC)(T)
Synonyms:
- 2,2-Dimethyl-5-(2,5-dimethylphenoxy)pentanoic Acid
- 2,2-Dimethyl-5-(2,5-dimethylphenoxy)valeric Acid
Product Documents:
| Size | Unit Price | Philadelphia, PA | Portland, OR | Japan* | Quantity |
|---|---|---|---|---|---|
| 5G |
$32.00
|
3 | 1 | ≥80 |
|
| 25G |
$96.00
|
1 | 1 | 12 |
|
* Items in stock locally ship in 1-2 business days. Items from Japan stock are able to ship from a US warehouse within 2 weeks. Please contact TCI for lead times on items not in stock. Excludes regulated items and items that ship on ice.
* To send your quote request for bulk quantities, please click on the "Request Quote" button. Please note that we cannot offer bulk quantities for some products.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.
| Product Number | G0368 |
| Purity / Analysis Method | >98.0%(GC)(T) |
| Molecular Formula / Molecular Weight | C__1__5H__2__2O__3 = 250.34 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Room Temperature (Recommended in a cool and dark place, <15°C) |
| CAS RN | 25812-30-0 |
| Reaxys Registry Number | 1881200 |
| PubChem Substance ID | 125307848 |
| SDBS (AIST Spectral DB) | 52970 |
| Merck Index (14) | 4388 |
| MDL Number | MFCD00079335 |
Specifications
| Appearance | White to Almost white powder to crystal |
| Purity(GC) | min. 98.0 % |
| Purity(Neutralization titration) | min. 98.0 % |
| Melting point | 57.0 to 62.0 °C |
Properties (reference)
| Melting Point | 61 °C |
| Boiling Point | 159 °C/0.02 mmHg |
| Solubility (soluble in) | Methanol |
GHS
| Pictogram |
|
| Signal Word | Warning |
| Hazard Statements | H302 : Harmful if swallowed. H413 : May cause long lasting harmful effects to aquatic life. |
| Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P273 : Avoid release to the environment. P270 : Do not eat, drink or smoke when using this product. P264 : Wash skin thoroughly after handling. P301 + P312 + P330 : IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. Rinse mouth. |
Related Laws:
| RTECS# | YV7120000 |
Transport Information:
| HS Number | 2918.99.4700 |
Application
Gemfibrozil: An Antilipemic Fibrate
The fibrates, including gemfibrozil, are lower elevated serum lipids by decreasing the low density lipoprotein (LDL) fraction rich in cholesterol and the very low density lipoprotein (VLDL) fraction rich in triglycerides. In addition, fibrates increase the high density lipoprotein (HDL) cholesterol fraction. The precise mechanisms of action remain unknown, but it has been reported that the major modes of action of the fibrates as follows: VLDL catabolism by increased lipoprotein and hepatic triglyceride lipase activities; suppression of triglyceride biosynthesis by acetyl-CoA carboxylase enzyme inhibition and attenuation of cholesterol biosynthesis by inhibition of the rate-limiting HMG-CoA reductase. In 2000s, it has been reported that concomitant use of gemfibrozil with statins (in particular cerivastatin) increases the risk of rhabdomyolysis which is a serious syndrome due to a muscle injury. (The product is for research purpose only.)
References
- Gemfibrozil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in dyslipidemia
- Gemfibrozil: a reappraisal of its pharmacological properties and place in the management of dyslipidemia
- Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation
- Gemfibrozil greatly increases plasma concentrations of cerivastatin
- Simultaneous quantitation of rosuvastatin and gemfibrozil in human plasma by high-performance liquid chromatography and its application to a pharmacokinetic study
- A high performance liquid chromatography method for simultaneous determination of rosiglitazone and gemfibrozil in human plasma
PubMed Literature
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.